Bispecific antibodies (BiTEs), which connect T cells to tumor cells by targeting CD3 on T cells and TAAs like EpCAM or CEA, have shown efficacy against KRAS- and BRAF-mutated CRC cells, where conventional therapies fail. Here, BRAF is linked to neoplasm.